



Press release

**Optimizing mesalazine treatment in the patient with mild to moderate ulcerative colitis**

Freiburg, October 3<sup>rd</sup>, 2021

**Meet the expert on inflammatory bowel disease, Dr Ayesha Akbar, at this year's Virtual UEG Week.**

Ulcerative colitis (UC) is one of a group of disorders known as inflammatory bowel disease (IBD). Other disorders within this group include Crohn's disease and two forms of microscopic colitis namely lymphocytic and collagenous colitis. UC is characterized by chronic inflammation of the gastrointestinal tract. Although this inflammation primarily affects the lower part of the digestive tract, it may also impact other parts of the colon.

For patients with UC, the action and delivery mechanism of their medication is crucial for successful management of the disease. This is where release characteristics of the drug come into play. The goal is to ensure that an adequate concentration of the drug is present at the site of inflammation.

Dr. Falk Pharma has developed outstanding expertise in topically, (locally), effective drugs for the intestinal tract, liver and oesophagus. This means, the pharmaceutical formulation of a drug is designed in such a way that the active ingredient is released exactly where it is needed inside the body. Additionally, the specific release characteristics allow the active ingredient to be released gradually over a certain period of time.

Dr Ayesha Akbar from St Marks Hospital in Harrow, UK, will discuss the importance of correct and effective treatment with mesalazine in patients with mild and moderate ulcerative colitis, at this year's UEG Week on October 4<sup>th</sup>. To register, click [>>here](#).

**Dr Ayesha Akbar, St Marks Hospital, Harrow, UK**

Dr Ayesha Akbar studied medicine at the University of Manchester gaining a degree with Honours and completed her postgraduate training including a PhD in London, before her appointment at St Mark's in 2010. Her clinical interests include inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). Dr Akbar was 3-year chair of the British Society of Gastroenterology (BSG) Education committee until July 2021. She holds several management roles, including interim Deputy Medical Director, Divisional Clinical Director of ICS, and Director of R&D. As a key opinion leader, she frequently lectures and chairs on a national and international basis, and is passionate about education, training and patient care.

**Ulcerative colitis**

Ulcerative colitis is one of the disorders known as inflammatory bowel disease (IBD). Other disorders within this group of conditions include Crohn's disease and two forms of microscopic colitis called lymphocytic and collagenous colitis.

IBD is characterized by chronic inflammation. Although this inflammation primarily affects the lower part of the digestive tract, the symptoms of these disorders can vary greatly depending on the condition and may also impact other parts of the body.

## Press release

Digital photographs in print-ready resolution are available to illustrate this press release. They may only be used for editorial purposes. Use is free of charge when credit is given as "Photo: Dr. Falk Pharma GmbH" or as stated below. Graphic editing – except for cropping out the main motif – is prohibited.



### Human intestines

IBD primarily affects the lower part of the digestive tract, the symptoms of these disorders can vary greatly depending on the condition and may also impact other parts of the body.

Photo: SciePro/shutterstock\_1414696697

### About Dr. Falk Pharma GmbH

Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of bowel, hepatic, biliary, and esophageal disorders like inflammatory bowel disease or eosinophilic esophagitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, with production sites in Germany, France, and Switzerland. Dr. Falk Pharma GmbH employs approximately 990 individuals globally and 214 in Freiburg.

Further information on Dr. Falk Pharma can be found online: <https://drfalkpharma.com>

More details on the UEG Week Virtual 2021 can be found at <https://ueg.eu/week>.

### Contact

#### Dr. Falk Pharma GmbH

Babette Kopp

Corporate Communications

Leinenweberstr. 5

79108 Freiburg

Germany

Phone: +49 761 1514-0

Email: [babette.kopp@drfalkpharma.de](mailto:babette.kopp@drfalkpharma.de)

[www.drfalkpharma.com](http://www.drfalkpharma.com)